| 34.5183 -0.517 (-1.47%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 44.2 |
1-year : | 46.83 |
| Resists | First : | 37.84 |
Second : | 40.09 |
| Pivot price | 36.07 |
|||
| Supports | First : | 34.2 |
Second : | 28.45 |
| MAs | MA(5) : | 35.43 |
MA(20) : | 35.97  |
| MA(100) : | 35.43 |
MA(250) : | 29.11 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.2 |
D(3) : | 11.8 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 40.09 | Low : | 18.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LFSC ] has closed below the lower bollinger band by 11.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ LFSC ] is to continue within current trading range. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.73 - 34.92 | 34.92 - 35.14 |
| Low: | 33.64 - 33.86 | 33.86 - 34.1 |
| Close: | 34.1 - 34.49 | 34.49 - 34.9 |
LFSC seeks to invest in innovative life sciences companies that are expected to create value and long-term growth. The actively managed fund relies on a specialized and experienced team to research complex life sciences companies. It invests in US equity securities identified to have growth potential that meet the criteria of technological advancement, market disruption, or artificial intelligence. The broad life science field includes biotechnology, pharmaceutical, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection employs an extensive 10-step research process that includes reviews of publicly available and third-party information, peer reviews, financial and valuation models, internal research, surveys, as well as interviews and contact with management, industry and medical professionals, supply chain, and collaboration within the investment team. The fund may invest up to 20% in foreign companies listed on a US exchange.
Thu, 22 Jan 2026
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
Wed, 31 Dec 2025
Best-Performing Active ETFs of 2025 - Nasdaq
Sat, 22 Nov 2025
LMRI Stock Price and Chart — NASDAQ:LMRI - TradingView
Mon, 06 Oct 2025
Emerald Advisers and F/m Investments Launch F/m Emerald Special Situations ETF (SPIT) - Business Wire
Sat, 15 Mar 2025
LFSC: A New Small-Cap Health Care ETF Prioritizing Innovation Before Profits (NASDAQ:LFSC) - Seeking Alpha
Sat, 14 Dec 2024
SBIO ETF: Betting On Medical Breakthroughs (NYSEARCA:SBIO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|